That acknowledged, the joint guidelines released by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) recommend GLP-1 receptor agonists as a preferred second-line treatment option in patients with established cardiovascular disease or high cardiovascular risk, and as a potential second-line therapy in populations with a compelling need to minimise hypoglycaemia or weight gain or promote weight loss [12]. This evidence concerns the gene GLP1R and cardiovascular disorder.